Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by... ORIGINAL ARTICLE PI3K/mTOR Signaling in Mesothelioma Patients  Treated with Induction Chemotherapy Followed by  Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,* Mayura Meerang, PhD,* Martina Friess, VMD,* Alex Soltermann, MD,† Lukas Frischknecht, MD,† Svenja Thies, MD,† Emanuela Felley-Bosco, PhD,‡ Ming-Sound Tsao, MD,§ Ghassan Allo, MD,§ Marc de Perrot, MD,║ Burkhardt Seifert, PhD,¶ Holger Moch, MD,† Rolf Stahel MD,‡ Walter Weder MD,* and Isabelle Opitz, MD* expression in samples before and after induction chemotherapy of Introduction: The prognostic significance of activity biomarkers cohort 1 revealed that decreased cytoplasmic PTEN and increased within the phosphatidylinositol 3-kinase (PI3K)/mammalian target phospho-mTOR expression was associated with a worse OAS of rapamycin (mTOR) signaling pathway was assessed in two inde- (p = 0.04 and p = 0.03, respectively). pendent cohorts of malignant pleural mesothelioma (MPM) patients Conclusions: These novel data reveal a prognostic significance of uniformly treated with a multimodal approach. We specifically expression changes of PI3K/mTOR pathway components during assessed expression signatures in a unique set of pre- and postchemo- induction chemotherapy if confirmed in other patient cohorts and therapy tumor samples. support the growing evidence to target the PI3K/mTOR pathway in Methods: Biomarker expression was assessed in samples of two the treatment of MPM. independent cohorts of 107 (cohort 1) and 46 (cohort 2) MPM http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy

Journal of Thoracic Oncology , Volume 9 (2) – Feb 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/pi3k-sol-mtor-signaling-in-mesothelioma-patients-treated-with-vLrsvai7OR

References (52)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000055
pmid
24419422
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE PI3K/mTOR Signaling in Mesothelioma Patients  Treated with Induction Chemotherapy Followed by  Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,* Mayura Meerang, PhD,* Martina Friess, VMD,* Alex Soltermann, MD,† Lukas Frischknecht, MD,† Svenja Thies, MD,† Emanuela Felley-Bosco, PhD,‡ Ming-Sound Tsao, MD,§ Ghassan Allo, MD,§ Marc de Perrot, MD,║ Burkhardt Seifert, PhD,¶ Holger Moch, MD,† Rolf Stahel MD,‡ Walter Weder MD,* and Isabelle Opitz, MD* expression in samples before and after induction chemotherapy of Introduction: The prognostic significance of activity biomarkers cohort 1 revealed that decreased cytoplasmic PTEN and increased within the phosphatidylinositol 3-kinase (PI3K)/mammalian target phospho-mTOR expression was associated with a worse OAS of rapamycin (mTOR) signaling pathway was assessed in two inde- (p = 0.04 and p = 0.03, respectively). pendent cohorts of malignant pleural mesothelioma (MPM) patients Conclusions: These novel data reveal a prognostic significance of uniformly treated with a multimodal approach. We specifically expression changes of PI3K/mTOR pathway components during assessed expression signatures in a unique set of pre- and postchemo- induction chemotherapy if confirmed in other patient cohorts and therapy tumor samples. support the growing evidence to target the PI3K/mTOR pathway in Methods: Biomarker expression was assessed in samples of two the treatment of MPM. independent cohorts of 107 (cohort 1) and 46 (cohort 2) MPM

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Feb 1, 2014

There are no references for this article.